medigraphic.com

2017, Number 4

<< Back Next >>

Rev Mex Anest 2017; 40 (4)

Anesthetic management of a patient with pregnancy of 34 weeks of gestation and diffuse hemangiomatosis

Rivera-Flores JL, Palacios-Lara JM, Germán-Olvera CE, Ortíz-Fraga CC, Rivera-Valdez IA, González-Monroy AD, Hernández-Alonso MA

Language: Spanish
References: 21
Page: 299-305
PDF size: 263.62 Kb.


ABSTRACT

Diffuse hemangiomatosis is a condition of benign behavior that is associated with embryonic development abnormal congenital generally related to the Nocht cells (perivascular cells, non-endothelial origin) associated with HYS genes. The evolution of these lesions is not the usual as injuries go through three stages: proliferative phase in the first year of life, in the second one remission and the third postremision with an apparently healthy behavior, this makes their prognosis variable; when injuries are perpetuated in obstetric patients may have special consideration especially when lesions invade hemangiomatous structures of the upper airways and neuraxial region from the skin to the invasion of medullary vessels. The invasion of the digestive tract is usually associated with frequent bleeding endangering the fetal maternal wellbeing, hemodynamically are classified as low-flow conditions. We report a case of diffuse hemangiomatosis and 34 weeks of pregnancy. It was performed a pre-anesthetic assessment, toracocervical and abdominal ultrasound and NMR, determining the anesthetic technique, opting for general anesthesia with endotracheal intubation without complications. The prognosis is poor by frequent gastrointestinal bleeding and the possibility of it happening neuraxial and / or upper airways.


REFERENCES

  1. Parres JB, Tarazona VP, Zambito BG. Hemangioma vertebral sintomático. An Med Asoc Med Hosp ABC. 1999;44:138-140.

  2. Tan ST, Hasan Q, Velickovic M, Rüger BM, Davis RP, Davis PF. A novel in vitro human model of hemangioma. Mod Pathol. 2000;13:92-99.

  3. 3 Vlastarakos PV, Papacharalampous GX, Chrysostomou M, Tavoulari EF, Delidis A, Protopapas D, Nikolopoulos TP. Review article propranolol is an effective treatment for airway haemangiomas: a critical analysis and meta-analysis of published interventional studies. Acta Otorhinolaryngol Ital. 2012;32:213-221.

  4. Callahan AB, Yoon MK. Infantile hemangiomas. A review. Saudi J Ophthalmol. 2012;26:283-291.

  5. Astencio RG, Más Martínez M. Hemangioma gigante del hígado. Rev Cubana Med. 2013;52:281-285.

  6. Gandolfi L, Leo P, Solmi L, Vitelli E, Verros G, Colecchia A. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut. 1991;32:677-680.

  7. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic haemangiomas: possible association with female sex hormone. Gut. 2004;53:1352-1355.

  8. Balma-Mena A, Lara-Corrales I. Clasificación, manejo y complicaciones de los Hemangiomas de la infancia. Acta Pediatr Costarric. 2010;22:7-13.

  9. Greenberger S, Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med. 2011;1(1):a006460. doi: 10.1101/cshperspect.a006460.

  10. Tingen VS, Martínez MC, Ramos RP, Montaño FE, Collazo JJ. Hemangiomatosis diseminada; una presentación poco frecuente. Rev Med Hosp Gen Mex. 2010;73:237-240.

  11. Eivazi B, Werner JA. Extracranial vascular malformations (hemangiomas and vascular malformations) in children and adolescents-diagnosis, clinic, and therapy. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2014;13:. doi: 10.3205/cto000105.

  12. Marchuk DA. Pathogenesis of hemangioma. J Clin Invest. 2001;107:665-666.

  13. Richter GT, Friedman AB. Hemangiomas and vascular malformations: current theory and management. Int J Pediatr. 2012;2012:645-678. doi: 10.1155/2012/645678.

  14. Mühmer M, Bostelmann R, Sarikaya-Seiwert S, Schneiderhan M, Steiger HJ, Cornelius JF. Clinical and radiological presentation of spinal epidural haemangiomas: clinical series in a tertiary care centre during a 10-year period. Eur Spine J. 2014;23:404-410.

  15. Mulliken JB, Glowacki J. Classification of pediatric vascular lesions. Plast Reconstr Surg. 1982;70:120-121.

  16. Adepoju O, Wong A, Kitajewski A, Tong K, Boscolo E, Bischoff J, et al. Expression of HES and HEY genes in infantile hemangiomas. Vasc Cell. 2011 Aug 11;3:19. doi: 10.1186/2045-824X-3-19.

  17. Arabi SJ, López GF. Hemangiomatosis neonatal difusa. Presentación de un caso y revisión de la literatura. Rev Mex Pediatr. 2000;67:270-273.

  18. Murillo M, Zarza M, Gómez S, Chica J, Carrasquilla R, de la Vega J y cols. Anestesia en embarazada para traqueostomía urgente por hemangioma sangrante en lengua. Rev Colomb Anestesiol. 2012;40:313-317.

  19. Shayan YR, Prendiville JS, Goldman RD. Use of propranolol in treating hemangiomas. Can Fam Physician. 2011;57:302-303.

  20. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life- threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.

  21. Frei-Jones M, McKinstry RC, Perry A, Leonard JR, Park TS, Rubin JB. Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr. 2008;2:125-129.




2020     |     www.medigraphic.com